Silence Therapeutics to discuss Phase 2 SANRECO trial topline results for divesiran in polycythemia vera

PUBT · 1d ago
Silence Therapeutics to discuss Phase 2 SANRECO trial topline results for divesiran in polycythemia vera
  • Silence Therapeutics scheduled an Aug. 10, 2026 conference call to discuss topline Phase 2 SANRECO results for divesiran in polycythemia vera.
  • Results have not yet been presented; the company plans to disclose the topline readout during the call and webcast.
  • The announcement did not describe the trial outcome or indicate whether divesiran met key study objectives.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Silence Therapeutics plc published the original content used to generate this news brief via Business Wire (Ref. ID: 20260809993728) on August 09, 2026, and is solely responsible for the information contained therein.